ndv-hxp-s
Vaccineexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 20, 2021 (NCT04764422)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215520 | Phase 2 | Nov 3, 2025 | CastleVax Inc. |
| NCT05354024 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2022 | Butantan Institute |
| NCT05181709 | Phase 1 | Feb 1, 2022 | Icahn School of Medicine at Mount Sinai |
| NCT04993209 | Phase 1/Phase 2 (Phase 2) | Jul 9, 2021 | Butantan Institute |
| NCT04764422 | Phase 1/Phase 2 (Phase 2) | Mar 20, 2021 | Mahidol University, The Government Pharmaceutical Organization |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Butantan Institute | Academic/Hospital | 2 | 2 | 2 | 2021 |
| CastleVax Inc. | For profit | 1 | 1 | 1 | 2025 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Mahidol University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| The Government Pharmaceutical Organization | Government | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1